Operational Resource Center

Clinical Trial Enrollment Resources

Practical guidance, carefully sourced resources, tools, templates, and applied examples for clinical trial intake, prescreening, candidate follow-up, coordinator capacity, and enrollment operations.

11Operational Resources
4Resource Categories
6Enrollment Pillars Covered

Pathway 02 · Review the Evidence

Review the Evidence and C2R Interpretation

Sourced guides identify what type of material supports a claim and separate that material from Consent2Randomize's operational interpretation. This pathway begins with one carefully sourced guide; it does not mean the complete article archive has already received the same source review.

Official Source

FDA, the HHS Office for Human Research Protections (OHRP), ClinicalTrials.gov, and other applicable authoritative sources.

Research

Peer-reviewed, academic, or credible institutional research.

Industry Data

Established datasets, surveys, and broader market research.

Provider-Reported Result

A provider’s own reported case-study or program result.

C2R Analysis

C2R calculations, models, interpretations, and operational frameworks.

C2R Results

Verified C2R customer performance data only after it exists.

No verified customer results published yet

35%

Referral response in one patient-referral pilot

Research

46 of 133 cancer patients received a response when Ancora.ai used contact information listed on ClinicalTrials.gov in the Tufts Center for the Study of Drug Development (Tufts CSDD)/Ancora.ai pilot.

Why it matters: Patient interest still needs a clear response and next step.

Evidence detail

Cancer-only, 17 countries, pilot data, and not a universal referral-response rate.

≈2×

Supported-site recruitment performance in provider-reported programs

Provider-Reported Result

IQVIA reported 35.21 patients per site at supported sites versus 16.36 at unsupported sites in one Phase III program. ICON separately reported more than twice the recruitment rate at Accellacare sites in another Phase III program.

Why it matters: These provider-reported programs show strong recruitment results at supported sites. They make the role of dedicated support worth examining, without proving that support alone caused the difference.

Evidence detail

Provider-reported and program-specific; not universal, not C2R performance, and not proof of one isolated intervention.

4.17×

Participants per active recruitment day

Research

A systematic review and meta-analysis found online recruitment yielded 4.17 times more participants per active recruitment day than offline recruitment in the seven-study active-day analysis.

Why it matters: The review found a large difference in one recruitment-speed measure between online and offline approaches. Acquisition is still only one part of enrollment.

Evidence detail

High heterogeneity; active recruitment days only; not the total recruitment period; offline conversion was higher in the conversion analysis.

≈$40K/day

Mean direct daily operating cost of later-stage trials

Research

Tufts CSDD researchers estimated the mean direct daily operating cost of Phase II and Phase III trials combined at about $40,000.

Why it matters: Later-stage trials are expensive to operate, which helps explain why enrollment timelines matter.

Evidence detail

Sponsor-level trial economics, not site revenue and not the guaranteed cost of one enrollment-delay day.

Assessments & Scorecards

Assessments & Scorecards

Structured assessments that help research sites review operational maturity, surface areas for closer review, and establish a site-defined enrollment-infrastructure baseline.

Calculators & Dashboards

Calculators & Dashboards

Data-driven tools that model enrollment scenarios, timelines, economics, and operational metrics using site-defined inputs and assumptions.